1 2 2	Short term DPA (22:5n-3) supplementation increases tissue DPA, DHA and EPA concentration in rats
3	
4 5 6	Gunveen Kaur ¹ , Denovan P Begg ^{2,3} , Daniel Barr ³ , Manohar Garg ⁴ , David Cameron- Smith ³ and Andrew J Sinclair ^{1,3}
7 8 9 10	
11 12	¹ Metabolic Research Unit, School of Exercise and Nutrition Sciences, Deakin University, Waurn Ponds, 3217, Victoria, Australia
13 14	² School of Psychological Science, La Trobe University, Bundoora, 3086, Victoria, Australia
15 16	³ School of Exercise and Nutrition Sciences, Deakin University, Burwood, 3126, Victoria, Australia
17 18 19	⁴ School of Health Science, University of Newcastle, Callaghan NSW 2308, Australia
20 21 22 23	Running Title: Metabolism of DPA (22:5n-3)
24 25 26 27 28 29 30	Key Words: Docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), eicosapentaenoic acid (EPA), n-3 polyunsaturated fatty acids (PUFA)
31 32 33	To whom correspondence should be addressed Andrew Sinclair
34 35 36	School of Exercise and Nutrition Sciences, 221 Bwd Hwy, Deakin University, Burwood, 3125, Victoria, Australia. Fax: +61-3-9251 7282
37 38 39	Phone +61-3-92446017 email andrew.sinclair@deakin.edu.au
40 41 42 43	Abbreviations: ALA, alpha-linolenic acid; EPA, eicosapentaenoic acid; DHA,
44 45 46 47	docosahexaenoic acid; DPA, docosapentaenoic acid; LCPn-3 long chain n-3 PUFA; OA, oleic acid; AA, Arachidonic acid;
48	

ABSTRACT

The metabolic fate of dietary n-3 docosapentaenoic acid (DPA) in mammals is currently unknown. The aim of this study was to determine the extent of conversion of dietary DPA to docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) in rats. Four groups of male weanling Sprague Dawley rats (aged 5 weeks) were given 50 mg of DPA, EPA, DHA or oleic acid, daily for 7 days by gavage. At the end of the treatment period the tissues were analysed for concentrations of long chain polyunsaturated fatty acids (PUFA). DPA supplementation led to significant increases in DPA concentration in all tissues, with largest increase being in adipose (5 fold) and smallest increase being in brain (1.1 fold). DPA supplementation significantly increased the concentration of DHA in liver and the concentration of EPA in liver, heart and skeletal muscle, presumably by the process of retroconversion. EPA supplementation significantly increased the concentration of EPA and DPA in liver, heart and skeletal muscle and the DHA concentration in liver. DHA supplementation elevated the DHA levels in all tissues and EPA levels in the liver. Adipose was the main tissue site for accumulation of DPA, EPA and DHA. This data suggests that dietary DPA can be converted to DHA in the liver, in a short term study, and that in addition it is partly retro-converted to EPA in liver, adipose, heart and skeletal muscle. Future studies should examine the physiological effect of DPA in tissues such as liver and heart.

- . _

84 INTRODUCTION

85

The interest in n-3 polyunsaturated fatty acids (PUFA) developed rapidly after two 86 Nobel Prize winning discoveries of particular prostaglandins, metabolites of arachidonic 87 acid, by Vane and Samuelson in the late 60's and early 70's ⁽¹⁾. Since then there have 88 been many studies suggesting the beneficial effects of n-3 fatty acids in reducing risk of 89 cardiovascular events, diabetes, inhibiting growth of tumour cells, modulating gene 90 expression and anti inflammatory activity ⁽²⁻⁷⁾. The parent n-3 PUFA is alpha-linolenic 91 acid (ALA; 18:3n-3), which is found in high concentration in some plant oils. In 92 93 mammals, some of the ingested ALA is metabolised to long chain n-3 PUFA (LCPn-3) namely eicosapentaenoic acid (EPA; 20:5n-3), docosapentaenoic acid (DPA; 22:5n-3) 94 95 and docosahexaenoic acid (DHA; 22:6n-3) by a series of desaturations and elongations (see Fig 1). This metabolic processing of ALA to DHA is inefficient ⁽⁸⁾ and much of the 96 97 ingested ALA is either deposited in tissue adipose stores as ALA or catabolised by mitochondrial beta-oxidation to yield energy (ATP) and carbon dioxide ⁽⁹⁾. Many 98 99 studies have reported that feeding relatively high levels of ALA in either animals or humans leads to increased DPA levels, but not DHA levels, suggesting the steps 100 between DPA and DHA are rate limiting steps in this metabolic pathway ^(10, 11). In 101 contrast, ingested DHA is rapidly and efficiently deposited in brain, liver and other 102 tissues ⁽¹²⁾. There is not much literature available on fate of DPA. Two cell culture 103 studies have looked at the effect of DPA supplementation in endothelial cells and 104 hepatocytes, respectively, and reported that DPA supplementation increases both DPA 105 and EPA levels but not DHA in these cells ^(13, 14). However, no animal studies have been 106 conducted to investigate the conversion of pure DPA to DHA in mammals, presumably 107 108 because DPA has only recently become available for in vivo studies (in milligram amounts). DPA is found in common foods like fish, fish oil, lean red meat and n-3-109 enriched eggs ⁽¹⁵⁾ therefore it is important to understand the metabolic fate of DPA. In 110 111 this paper we report the effect of DPA supplementation on DPA, EPA and DHA concentrations in rat tissues. The hypothesis being tested was that dietary 112 supplementation of DPA will increase both tissue DHA and EPA levels. The novelty of 113 this study is that it focuses on the metabolism of DPA in a rodent model, which has not 114 115 been investigated before.

117 MATERIALS AND METHODS

118

119 Animals and diets

Thirty two 4-wk-old male weanling Sprague Dawley rats were randomly divided into 120 four groups of eight animals. The rats were maintained on an *ad libitum* normal chow 121 122 diet with water, throughout the study. The total lipid content of the chow diet used was 5.7 (g/100g of wet weight) and the three main unsaturated fatty acids present in the 123 chow diet were oleic acid (OA) (29.7%), linoleic acid (31.2%) and ALA (3.4%); EPA, 124 125 DPA and DHA were not detected. The rats were pair housed and allowed one week to acclimatise. The rats were then administered 50mg of DPA, EPA, DHA or OA (Nu-126 127 Chek Prep, Inc, USA) by daily oral gavaging for 7 days. The dose and duration used in this study was based on evidence from previously published studies which have 128 129 successfully used doses of 90-100mg/d of PUFA, for rats weighing up to 140-220g. These studies demonstrated that changes in fatty acid composition of long chain PUFA 130 occured within 3 days of supplementation ⁽¹⁶⁻¹⁹⁾. In the present study, we used 50mg of 131 fatty acids for animals weighing 68-101g. Thus, it was expected that the dose of 50mg 132 133 of fatty acids given for 7 days would be sufficient to detect changes in tissue fatty acid composition. 134

The weight of the animals was recorded every day and on the 8th day the animals were sacrificed by lethal injection of Lethobarb (Virbac, NSW, Australia). Brain, heart, epididymal fat (adipose), skeletal muscle and liver were removed from the animals, washed in ice-cold saline (0.9% NaCl solution), and then dried on paper towel. After weighing the tissues were wrapped in foil and stored at -80°C for fatty acid analysis.

140

141 *Lipid analysis*

The tissues were minced and the tissue lipids were extracted by chloroform/methanol 142 2:1, as described by Sinclair et al ⁽²⁰⁾. An aliquot of the total lipids from each tissue, plus 143 144 an internal standard of docosatrienoic acid (22:3) (Nu-Chek Prep.USA), was reacted with 2% H₂SO₄ in methanol for 3 hours at 80°C to form the fatty acid methyl esters; 145 146 they were passed through a silica sep-pak to remove cholesterol and then the fatty acid 147 methyl esters were separated by capillary gas liquid chromatography using a 50 m x 148 0.32 mm (I.D.) fused silica bonded phase column (BPX70, SGE, Melbourne, Australia). The column oven was programmed to rise after 3 min at 125° to 220°C at 8°C/min with 149 a helium flow rate of 43 cm/sec as the carrier gas. Fatty acids were identified by 150

Metabolism of DPA (22:5n-3)

comparison with standard mixtures of fatty acid methyl esters and the results were
 calculated using response factors derived from chromatographing standards of known
 composition (NuChek Prep., Inc, USA).

154

155 Statistical analysis

Data analysis was performed using SPSS v15.0 for Windows (SPSS Inc., Chicago, IL). Significant differences between dietary groups were tested using a one-way ANOVA for each type of fatty acid for both fatty acid analysis and gene expression. Post-hoc comparisons were made using the LSD (least significant difference) test with a significance level of 0.05.

161

162 *Ethics approval*

All experimental procedures involving animals were performed under the 'Australian code of practice for the care and use of animals for scientific purposes' and were approved by La Trobe University Animal Ethics Committee (AEC07-53-P) and Deakin University Animal Welfare Committee (AEX 23/2008).

167

168 **RESULTS**

169

170 Body and tissue weights

There was no significant difference in the body weights of animals between various dietary groups at the start and the end of the study. The mean (\pm SD) body weights of rats at the start and end of study were 75.9 \pm 5.8 and 122.4 \pm 17.4 grams, respectively. There were no significant differences in the tissue weights between treatments.

175

176 *Tissue fatty acid concentrations*

Adipose tissue contained the highest concentration of each of the three long chain n-3PUFA with amounts ranging from 30 to 57 mg/g tissue compared with values of less than 3 mg/g in other tissues (Table 1). In liver, muscle & brain tissue, the concentration of DHA was between 1 to 3 mg/g; for DPA, the concentration ranged from 0.1 to 2mg/g while for EPA the range was from 0.02 to 0.4mg/g tissue. The rats supplemented with DHA showed a significant increase in tissue DHA content in all the five tissues studied. The largest proportional increase in DHA occurred in adipose (3.4 fold) and skeletal muscle (2.4 fold) and the least change was in brain (1.1 fold). It was also observed that
DHA supplementation led to a significant increase in EPA concentration in liver.

DPA supplementation resulted in statistically significant accumulation of DPA in all tissues analysed except adipose tissue. DPA supplementation also led to a significant increase in EPA concentrations in liver, heart and skeletal muscle and a nonsignificant increase in adipose tissue. Interestingly, DPA supplementation also led to a significant increase in DHA concentration in liver.

Supplementation with EPA led to a significant increase in tissue EPA and DPA concentrations in liver, heart and skeletal muscle and a non-significant increase in adipose tissue. EPA supplementation also increased DHA concentrations significantly in liver. All the three n-3 PUFA led to a significant decrease in AA concentrations in liver and heart.

196

197 DISCUSSION

The aim of this study was to examine the effect of DPA supplementation on LCPn-3 proportions in the tissues of animals fed 50mg of n-3 fatty acids per day for 7 days. It was observed that the primary site of DPA deposition was adipose followed by heart, liver and skeletal muscle. Adipose was also the main site for deposition of fed EPA and DHA in this study. Fu and Sinclair, reported that major sites of EPA and DPA deposition, in guinea pigs fed with diets containing 17.3% ALA (of total diet lipid) for 4 weeks, were adipose, skin and carcass ⁽¹⁰⁾.

It was observed that DPA supplementation increased DPA concentration in 205 206 liver, heart, skeletal muscle and brain. It was also observed that DPA supplementation 207 led to a significant increase in EPA concentrations in liver, heart and skeletal muscle 208 and a non-significant increase in EPA concentrations in adipose tissue suggesting the 209 retroconversion of DPA into EPA in vivo. The process of retroconversion was first described by Stoffel et al for DHA (21) and subsequent work by Christensen et al in 210 211 human fibroblasts indicated the retroconversion of DHA and DPA were both likely to involve the peroxisomal acyl-CoA oxidase (22, 23). Retroconversion of DPA into EPA 212 has also been reported in endothelial cells, fetal skin fibroblasts and hepatocytes (13, 14, 213 24) "apparent" DPA 214 The extent of retroconversion of to EPA $(\Delta EPA*100/\Delta [DPA+EPA])$ was 28% in liver, 19% in adipose tissue, 12% in skeletal 215 muscle, 4% in heart and negligible in brain. 216

It was also observed from our study that EPA fed animals showed a significant 217 218 increase in EPA and DPA concentrations in the liver, heart and skeletal muscle. These data confirm the findings of previously published cell culture studies which showed that 219 EPA is converted into DPA in endothelial and liver cells ^(13, 14). It is evident from our 220 study that EPA and DPA are interconverted in the body and therefore DPA may act as a 221 222 source of EPA in the body and vice-versa. This is particularly relevant in adipose tissue which had the highest concentrations of these PUFA and consequently adipose may act 223 224 as a reservoir of these fatty acids. Supplementation with EPA had no effect on brain 225 EPA levels which are known to very low (in this study 0.02mg/g). It has recently been suggested that low levels of EPA in brain phospholipids compared to DHA may be the 226 result of its rapid beta oxidation upon uptake by the brain ⁽²⁵⁾. 227

Another very significant finding of our study was that supplementation of rats 228 229 with DPA led to a significant increase in liver DHA concentrations and a non-230 significant increase in brain, compared with the control group fed OA. The DPA fed 231 group showed a 60% increase in liver DHA compared with the group fed DHA. Liver is regarded as a major site for PUFA synthesis ⁽⁹⁾ and since this was short-term study only, 232 233 there may have been insufficient time for the increased liver DHA to be delivered to the 234 other tissues via plasma lipoprotein transport. The two previously published cell culture studies that have looked at DPA supplementation failed to demonstrate an increase in 235 tissue DHA levels. It is not clear whether this was due to a limited ability of these 236 particular cells to desaturate PUFA or to competition between 24:5n-3 and ALA for 237 metabolism to DHA⁽²⁶⁾. 238

In this study, the DHA fed group was regarded as a control group to judge the 239 effectiveness of increases in DHA concentration in the EPA- and DPA-fed groups. 240 241 There was an increase in the tissue DHA concentrations in the DHA-fed group with the largest rise occuring in adipose tissue (3.4 fold), followed by skeletal muscle (2.4 fold), 242 heart (2.1 fold), liver (1.76 fold) and brain (1.1 fold). It was no surprise that significant 243 244 increases in DHA were observed as this has been observed by many groups in a variety of dietary supplementation studies (26-28). It was also observed that DHA 245 246 supplementation increased the EPA levels in liver suggesting retroconversion into EPA.

In this study, DPA, EPA and DHA supplementation also led to a significant decrease in tissue AA levels in liver and heart and a non significant decrease in muscle and adipose. This could be explained by the fact that n-3LCP are known to have an inhibitory effect on delta 6 and delta 5 desaturases (29, 30), which are involved in

synthesis of AA from linoleic acid. Also supplementation of cells with the LCPn-3 251 could have led to competition for the enzyme acyl CoA transferase thereby decreasing 252 the incorporation of AA into phospholipids $^{(31)}$. 253

To our knowledge, so far there have been very few studies which have

254

investigated the biochemical effects of DPA. We expect this might be due to the 255 relatively limited availability and high cost of pure DPA. But in light of the present 256 257 literature it can be speculated that the metabolic consequenses of accumulation of DPA 258 in tissues may be related accumulation of DPA, EPA and DHA from DPA and to 259 inhibition of AA metabolism. Two studies are worth mentioning since both reported an effect of pure DPA on platelet function through AA pathway inhibition ^(32, 33). One 260 study reported that platelets metabolize 22:5n-3 into 11- and 14-hydroxy 261 docosapentaenoic acids via an indomethacin-insensitive pathway (32). They also reported 262 263 that when DPA is released along with AA in platelets it inhibited cycloxygenase (COX) 264 enzyme thereby reducing the thromboxin B2 and 5,8,10-heptadecatrienoic acid (HHT) 265 production from AA. Akiba et al (2000) looked at the effects of DPA on platelet aggregation and AA metabolism in rabbit platelets and compared them with those of 266 EPA and DHA⁽³³⁾. The results showed that n-3 fatty acids inhibited collagen- or AA-267 stimulated platelet aggregation dose-dependently, and that DPA was the most potent 268 inhibitor. These results suggest that DPA possesses potent activity for interfering with 269 the COX pathway and accelerating the lipoxygenase pathway. 270

271 In conclusion, the data presented in our study demonstrated that oral 272 consumption of dietary DPA in young male rats increased the concentration of DHA in liver but not other tissues. Furthermore, DPA was partially retroconverted to EPA in 273 274 liver, muscle, adipose and heart. Future studies should investigate the physiological & 275 biochemical effects of DPA ingestion compared with that of EPA and DHA.

276 277


278 ACKNOWLEDGMENTS

279 This research was funded by Meat and Livestock Australia (Project code: D.MHN.0022) and by cluster funds from Faculty of Health Medicine Nursing and 280 Behavioural Sciences, Deakin University. 281

282 There is no conflict of interest of any personal, financial or academic nature, among the 283 authors.

Metabolism of DPA (22:5n-3)

284 Contribution of authors: Gunveen Kaur and Andrew Sinclair designed the study. 285 Denovan Begg co-ordinated and carried out the animal procedures with Gunveen Kaur. 286 Daniel Barr performed the fatty acid analysis. Gunveen Kaur performed the gene 287 expression analysis and statistical analysis of all the data. Gunveen Kaur wrote the 288 manuscript. Andrew Sinclair, Manohar Garg, David Cameron-Smith and Denovan Begg 289 along with Gunveen Kaur, contributed to the final version of the manuscript.





310	Figure	1: Pathway	for	metabolism	of ALA	to lo	ng chain	n-3	PUFA.

In mammals, some of the ingested ALA is metabolised to long chain n-3 fatty acids by series of elongations and desaturations. The figure shows the enzymes involved in this pathway. PUFA, polyunsaturated fatty acids; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid and DHA, docosahexaenoic acid.

Alpha linolenic acid (ALA)

TABLE 1: Tissue fatty acid concentrations in brain, adipose and skeletal muscle of

325 animals in various dietary groups (mean ± SD)

Fatty acids	OA Control		EPA Gr	oup	DPA G	roup	DHA Group	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Brain								
OA	2.97 ^a	0.03	3.03 ^{ab}	0.05	3.12 ^b	0.05	3.10 ^{ab}	0.06
AA	2.01 ^a	0.05	2.01 ^a	0.04	2.03 ^a	0.03	1.98 ^a	0.05
EPA	0.02^{a}	0.00	0.02^{a}	0.00	0.02^{a}	0.00	0.03 ^a	0.00
DPA	0.08^{a}	0.01	0.10^{b}	0.01	0.11 ^b	0.01	0.07^{a}	0.00
DHA	2.50^{a}	0.05	2.62 ^{ab}	0.03	2.65 ^{ab}	0.06	2.70^{b}	0.08
Adipose								
OA	948.33 ^a	64.66	1031.55 ^a	119.07	823.57 ^a	62.55	703.85 ^b	50.27
AA	40.48^{a}	4.64	36.28 ^a	5.79	31.88 ^a	2.95	29.28^{a}	3.73
EPA	3.87 ^a	0.50	30.42 ^a	7.95	14.37 ^a	4.32	5.29 ^a	0.90
DPA	11.00^{a}	2.48	29.96 ^a	9.07	55.68 ^a	13.73	23.48^{a}	5.43
DHA	16.62^{a}	1.20	23.20 ^{ab}	3.16	27.01 ^{ab}	3.03	57.04 ^a	10.23
Skeletal Muscle								
OA	3.98 ^a	0.68	3.95 ^a	0.62	3.35 ^a	0.48	3.62 ^a	0.45
AA	1.48 ^a	0.08	1.26 ^a	0.03	1.23 ^a	0.03	1.22 ^a	0.02
EPA	0.03 ^a	0.00	0.23 ^b	0.04	0.11 ^{bc}	0.01	0.04 ^{ac}	0.01
DPA	0.27^{a}	0.27	0.50^{b}	0.03	0.87^{c}	0.06	0.21 ^a	0.02
DHA	0.55 ^a	0.04	0.66 ^b	0.03	0.61 ^{ab}	0.02	1.31 ^c	0.05

Fatty acid composition of various tissues from rats supplemented with 50 mg of OA, EPA, DPA or DHA for 7 days. Results are expressed as mg/g of tissue (n=8). Mean±SD values within a row with unlike superscripts were significantly different (P<0.05). Data was analysed using one way ANOVA and post hoc comparisons were made using LSD. OA, Oleic acid; EPA, eicosapentaenoic acid; DPA, Docosapentaenoic acid; DHA, Docosahexaenoic acid.





Figure 2: Fatty acid composition of liver tissue of rats supplemented with 50 mg of OA, EPA, DPA or DHA for 7 days. Results are expressed as mg/g of tissue (n=8). Data was analysed using one way ANOVA and post hoc comparisons were made using LSD. Different superscripts represent significant difference from control OA group.

OA, Oleic acid; EPA, eicosapentaenoic acid; DPA, Docosapentaenoic acid; DHA,
 Docosahexaenoic acid.

351 352



DPA or DHA for 7 days. Results are expressed as mg/g of tissue (n=8). Data was analysed using one way ANOVA and post hoc comparisons were made using LSD. Different superscripts represent significant difference from control OA group.

OA, Oleic acid; EPA, eicosapentaenoic acid; DPA, Docosapentaenoic acid; DHA,
 Docosahexaenoic acid.

365		References
366	1.	Raju TN. The Nobel chronicles. 1982: Sune Karl Bergstrom (b 1916); Bengt Ingemar
367		Samuelsson (b 1934); John Robert Vane (b 1927). Lancet 1999;354(9193):1914.
368	2.	Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, Petasis NA, et al. Resolvin
369		E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid,
370		protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad
371		Sci U S A 2005;102(21):7671-6.
372	3.	Aktas H, Halperin JA. Translational regulation of gene expression by omega-3 fatty
373		acids. J Nutr 2004;134(9):2487S-2491S.
374	4.	Tsuji M, Murota SI, Morita I. Docosapentaenoic acid (22:5, n-3) suppressed tube-
375		forming activity in endothelial cells induced by vascular endothelial growth factor.
376		Prostaglandins Leukot Essent Fatty Acids 2003;68(5):337-42.
377	5.	Kitajka K, Puskas LG, Zvara A, Hackler L, Jr., Barcelo-Coblijn G, Yeo YK, et al.
378	-	The role of n-3 polyunsaturated fatty acids in brain: modulation of rat brain gene
379		expression by dietary n-3 fatty acids. Proc Natl Acad Sci U S A 2002;99(5):2619-24.
380	6.	Fujikawa M, Yamazaki K, Hamazaki T, Wakaki K, Koizumi F, Yano S, et al. Effect
381		of eicosapentaenoic acid ethyl ester on albuminuria in streptozotocin-induced
382		diabetic rats. J Nutr Sci Vitaminol (Tokyo) 1994;40(1):49-61.
383	7.	Shimizu H, Ohtani K, Tanaka Y, Sato N, Mori M, Shimomura Y. Long-term effect of
384		eicosapentaenoic acid ethyl (EPA-E) on albuminuria of non-insulin dependent
385		diabetic patients. Diabetes Res Clin Pract 1995;28(1):35-40.
386	8.	Brenna JT, Salem N, Jr., Sinclair AJ, Cunnane SC. alpha-Linolenic acid
387		supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in
388		humans. Prostaglandins Leukot Essent Fatty Acids 2009;80(2-3):85-91.
389	9.	Sinclair AJ, Attar-Bashi NM, Li D. What is the role of alpha-linolenic acid for
390		mammals? Lipids 2002;37(12):1113-23.
391	10.	Fu Z, Sinclair AJ. Increased alpha-linolenic acid intake increases tissue alpha-
392		linolenic acid content and apparent oxidation with little effect on tissue
393		docosahexaenoic acid in the guinea pig. Lipids 2000;35(4):395-400.
394	11.	Attar-Bashi NM, Li D, Sinclair AJ. Does conjugated linoleic acid increase
395		conversion of a-linolenic acid to docosahexaenoic acid in humans? Asia Pac J Clin
396		Nutr 2003;12 Suppl:S44.
397	12.	Sinclair AJ. Incorporation of radioactive polyunsaturated fatty acids into liver and
398		brain of developing rat. Lipids 1975;10(3):175-84.
399	13.	Pawar A, Jump DB. Unsaturated fatty acid regulation of peroxisome proliferator-
400		activated receptor alpha activity in rat primary hepatocytes. J Biol Chem
401		2003;278(38):35931-9.
402	14.	Benistant C, Achard F, Ben Slama S, Lagarde M. Docosapentaenoic acid (22:5,n-3):
403		metabolism and effect on prostacyclin production in endothelial cells. Prostaglandins
404		Leukot Essent Fatty Acids 1996;55(4):287-92.
405	15.	Mann NJ, Johnson LG, Warrick GE, Sinclair AJ. The arachidonic acid content of the
406		Australian diet is lower than previously estimated. J Nutr 1995;125(10):2528-35.
407	16.	Mann NJ, Warrick GE, O'Dea K, Knapp HR, Sinclair AJ. The effect of linoleic,
408		arachidonic and eicosapentaenoic acid supplementation on prostacyclin production in
409		rats. Lipids 1994;29(3):157-62.
410	17.	Williams MA, Tinoco J, Yang YT, Bird MI, Hincenbergs I. Feeding pure
411		docosahexaenoate or arachidonate decreases plasma triacylglycerol secretion in rats.
412		Lipids 1989;24(9):753-8.

- 413 18. Sanigorski AJ, Sinclair AJ, Hamazaki T. Platelet and aorta arachidonic and
 414 eicosapentaenoic acid levels and in vitro eicosanoid production in rats fed high-fat
 415 diets. Lipids 1996;31(7):729-35.
- Huang YS, Mitchell J, Jenkins K, Manku MS, Horrobin DF. Effect of dietary
 depletion and repletion of linoleic acid on renal fatty acid composition and urinary
 prostaglandin excretion. Prostaglandins Leukot Med 1984;15(2):223-8.
- Sinclair AJ, O'Dea K, Dunstan G, Ireland PD, Niall M. Effects on plasma lipids and fatty acid composition of very low fat diets enriched with fish or kangaroo meat. Lipids 1987;22(7):523-9.
- Stoffel W, Eker, Assad H, Sprecher H. Enzymatic studies on the mechanism of the
 retroconversion of C22-polyenoic fatty acids to their C20-homologues. Hoppe
 Seylers Z Physiol Chem 1970;351(12):1545-54.
- Christensen E, Woldseth B, Hagve TA, Poll-The BT, Wanders RJ, Sprecher H, et al.
 Peroxisomal beta-oxidation of polyunsaturated long chain fatty acids in human
 fibroblasts. The polyunsaturated and the saturated long chain fatty acids are
 retroconverted by the same acyl-CoA oxidase. Scand J Clin Lab Invest Suppl
 1993;215:61-74.
- Reddy JK, Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferatoractivated receptor alpha: an adaptive metabolic system. Annu Rev Nutr 2001;21:193230.
- 433 24. Rosenthal MD, Garcia MC, Jones MR, Sprecher H. Retroconversion and delta 4
 434 desaturation of docosatetraenoate (22:4(n-6)) and docosapentaenoate (22:5(n-3)) by
 435 human cells in culture. Biochim Biophys Acta 1991;1083(1):29-36.
- 436 25. Chen CT, Liu Z, Ouellet M, Calon F, Bazinet RP. Rapid beta-oxidation of
 437 eicosapentaenoic acid in mouse brain: an in situ study. Prostaglandins Leukot Essent
 438 Fatty Acids 2009;80(2-3):157-63.
- 439 26. Portolesi R, Powell BC, Gibson RA. Competition between 24:5n-3 and ALA for {Delta}6 desaturase may limit the accumulation of DHA in HepG2 cell membranes.
 441 J Lipid Res 2007;48(7):1592-8.
- Ward GR, Huang YS, Xing HC, Bobik E, Wauben I, Auestad N, et al. Effects of
 gamma-linolenic acid and docosahexaenoic acid in formulae on brain fatty acid
 composition in artificially reared rats. Lipids 1999;34(10):1057-63.
- 28. Nasrollahzadeh J, Siassi F, Doosti M, Eshraghian MR, Shokri F, Modarressi MH, et
 al. The influence of feeding linoleic, gamma-linolenic and docosahexaenoic acid rich
 oils on rat brain tumor fatty acids composition and fatty acid binding protein 7
 mRNA expression. Lipids Health Dis 2008;7:45.
- Garg ML, Sebokova E, Thomson AB, Clandinin MT. Delta 6-desaturase activity in
 liver microsomes of rats fed diets enriched with cholesterol and/or omega 3 fatty
 acids. Biochem J 1988;249(2):351-6.
- 452 30. Cho HP, Nakamura M, Clarke SD. Cloning, expression, and fatty acid regulation of 453 the human delta-5 desaturase. J Biol Chem 1999;274(52):37335-9.
- 454 31. Lands WE, Libelt B, Morris A, Kramer NC, Prewitt TE, Bowen P, et al. Maintenance
 455 of lower proportions of (n 6) eicosanoid precursors in phospholipids of human
 456 plasma in response to added dietary (n 3) fatty acids. Biochim Biophys Acta
 457 1992;1180(2):147-62.
- 458 32. Careaga MM, Sprecher H. Synthesis of two hydroxy fatty acids from 7,10,13,16,19459 docosapentaenoic acid by human platelets. J Biol Chem 1984;259(23):14413-7.
- Akiba S, Murata T, Kitatani K, Sato T. Involvement of lipoxygenase pathway in
 docosapentaenoic acid-induced inhibition of platelet aggregation. Biol Pharm Bull
 2000;23(11):1293-7.

Metabolism of DPA (22:5n-3)